{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:01:27Z","timestamp":1780426887927,"version":"3.54.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"abstract":"<jats:p>\n                    This study aimed to investigate the long-term health impacts of macrolide-resistant macrolide-resistant\n                    <jats:italic toggle=\"yes\">Mycoplasma pneumoniae<\/jats:italic>\n                    (MRMP) infection in children, identify factors influencing MRMP infection, and provide evidence for clinical decision-making to improve prognosis and address challenges posed by antimicrobial resistance. A case-control study was conducted, enrolling 64 pediatric MRMP-infected patients (research group) and 266 macrolide-sensitive macrolide-sensitive\n                    <jats:italic toggle=\"yes\">M pneumoniae<\/jats:italic>\n                    -infected patients (control group) admitted to our hospital from August 2023 to April 2024. All participants underwent standardized evaluations, including physical examinations, medical history review, complete blood count, blood biochemistry, inflammatory marker assays, and immunological profiling. The research group exhibited a lower incidence of fever compared to the control group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01). Respiratory assessments revealed significantly reduced rates of wet rales, intercostal retractions, and lung consolidation in the research group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Hematologically, the research group demonstrated lower white blood cell counts (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). Biochemical analysis indicated decreased alanine aminotransferase and urea levels (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), elevated lactate dehydrogenase (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), and comparable creatine kinase and creatine kinase-MB (CK-MB) levels between groups. C-reactive protein was significantly elevated in the research group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), while immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin E (IgE) levels remained comparable. Multivariate logistic regression analysis adjusting for potential confounders identified lung consolidation (OR\u2005=\u200565.79, 95% CI: 20.86\u2013207.49) and alanine aminotransferase levels (OR\u2005=\u20050.90, 95% CI: 0.82\u20130.99) as independent predictors of MRMP infection (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). MRMP and macrolide-sensitive\n                    <jats:italic toggle=\"yes\">M pneumoniae<\/jats:italic>\n                    infections in children present distinct clinical profiles and long-term prognoses. MRMP-infected children demonstrate elevated risks of recurrent respiratory infections and potential long-term respiratory sequelae, underscoring the necessity for rigorous acute-phase lung consolidation monitoring and extended respiratory function surveillance to optimize outcomes.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044302","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:03:20Z","timestamp":1759248200000},"page":"e44302","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative study of clinical characteristics and long-term prognosis between macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae infections in children: A retrospective case-control study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7132-0840","authenticated-orcid":false,"given":"Nanyue","family":"Zhou","sequence":"first","affiliation":[{"name":"The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Mo","sequence":"additional","affiliation":[{"name":"The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liang","sequence":"additional","affiliation":[{"name":"The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260602","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond.","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R2-20260602","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment.","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"R3-20260602","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00484-024-02712-7","article-title":"Effect of meteorological factors on the incidence of Mycoplasma pneumoniae pneumonia in Japan: a time series analysis.","volume":"68","author":"Wagatsuma","year":"2024","journal-title":"Int J Biometeorol"},{"key":"R4-20260602","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/INF.0000000000000171","article-title":"Mycoplasma pneumoniae infections in childhood.","volume":"33","author":"Atkinson","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20260602","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12098-020-03301-3","article-title":"Macrolide resistant mycoplasma pneumoniae in community acquired pneumonia.","volume":"87","author":"Varghese","year":"2020","journal-title":"Indian J Pediatr"},{"key":"R6-20260602","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/antibiotics12111623","article-title":"Characteristics of the Mycoplasma pneumoniae epidemic from 2019 to 2020 in Korea: macrolide resistance and co-infection trends.","volume":"12","author":"Shin","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R7-20260602","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/392498","article-title":"Mycoplasma pneumoniae and asthma in children.","volume":"38","author":"Biscardi","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R8-20260602","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cir625","article-title":"Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R9-20260602","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijid.2019.03.028","article-title":"Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China.","volume":"83","author":"Qu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R10-20260602","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/jac\/dkac170","article-title":"Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and meta-analysis.","volume":"77","author":"Wang","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R11-20260602","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","article-title":"Clinical efficacy of macrolide antibiotics against genetically confirmed macrolide-resistant mycoplasma pneumoniae pneumonia in pediatric patients.","volume":"17","author":"Kawai","year":"2012","journal-title":"Respirology"},{"key":"R12-20260602","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.pedneo.2021.05.017","article-title":"Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan.","volume":"62","author":"Chang","year":"2021","journal-title":"Pediatr Neonatol"},{"key":"R13-20260602","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.01806-13","article-title":"More complications occur in macrolide-resistant than in macrolide-sensitive mycoplasma pneumoniae pneumonia.","volume":"58","author":"Zhou","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20260602","doi-asserted-by":"crossref","first-page":"1478087","DOI":"10.3389\/fcimb.2024.1478087","article-title":"Increased in vitro antimicrobial resistance of Mycoplasma pneumoniae isolates obtained from children in Beijing, China, in 2023.","volume":"14","author":"Jia","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"R15-20260602","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00737-13","article-title":"Macrolide-resistant mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy.","volume":"57","author":"Miyashita","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20260602","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/AAC.00048-13","article-title":"Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant mycoplasma pneumoniae pneumonia in pediatric patients.","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20260602","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s10156-010-0044-X","article-title":"Pathogenesis of extrapulmonary manifestations of mycoplasma pneumoniae infection with special reference to pneumonia.","volume":"16","author":"Narita","year":"2010","journal-title":"J Infect chemother"},{"key":"R18-20260602","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1378\/chest.125.2_suppl.70S","article-title":"Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.","volume":"125","author":"Rubin","year":"2004","journal-title":"Chest"},{"key":"R19-20260602","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1078\/1438-4221-00231","article-title":"Subtyping of mycoplasma pneumoniae isolates based on extended genome sequencing and on expression profiles.","volume":"292","author":"Dumke","year":"2003","journal-title":"Int J Med Microbiol"},{"key":"R20-20260602","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2500\/aap.2014.35.3742","article-title":"The role of Mycoplasma pneumoniae infection in the initial onset and exacerbations of asthma.","volume":"35","author":"Watanabe","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"R21-20260602","first-page":"224","article-title":"Inflammatory immune responses by mycoplasma pneumoniae: pathogenicity and host immunity.","volume":"7","author":"Shimizu","year":"2016","journal-title":"Front Microbiol"},{"key":"R22-20260602","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ppul.20374","article-title":"Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children.","volume":"41","author":"Lee","year":"2006","journal-title":"Pediatr Pulmonol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:03:19Z","timestamp":1780423399000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":22,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044302","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"2025-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}